Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 26:44:101094.
doi: 10.1016/j.gore.2022.101094. eCollection 2022 Dec.

Stage and outcomes of invasive cervical cancer patients in Botswana: A prospective cohort study from 2013 to 2020

Surbhi Grover  1   2 , Jessica George  3 , Shawna Tuli  3 , Katie Lichter  4 , Rohini Bhatia  5 , Barati Monare  2 , Ganen Chinniah  6 , Lisa Bazzett-Matabele  7 , Memory Bvochora-Nsingo  8 , Sebathu Chiyapo  9 , Dawn Balang  8 , Tlotlo Ralefala  9 , Peter Vuylsteke  10 , Rebecca Luckett  11 , Sanghyuk Shin  12 , Nicola Zetola  1   2 , Doreen Ramogola-Masire  11
Affiliations

Stage and outcomes of invasive cervical cancer patients in Botswana: A prospective cohort study from 2013 to 2020

Surbhi Grover et al. Gynecol Oncol Rep. .

Abstract

Objective: To present the stage distribution, patterns of care, and outcomes of patients from Botswana with invasive cervical cancer, living with or without HIV.

Methods: Between 2013 and 2020, women with cervical cancer were prospectively enrolled in an observational cohort study.

Results: A total of 1,043 patients were enrolled; 69% were women living with HIV. The median age of the cohort was 47 years (interquartile range [IQR] 40-58 years), with women living with HIV presenting at a younger age compared to women without HIV (44 versus 61 years, p < 0.001). Among women living with HIV, the median CD4 count at the time of cancer diagnosis was 429.5 cells/μL (IQR 240-619.5 cells/μL), 13% had a detectable viral load, and 95% were on antiretroviral therapy. In regard to treatment, 6% (n = 58) underwent surgery, 33% (n = 341) received radiation therapy, 51% (n = 531) received chemoradiation, and 7% (n = 76) did not receive treatment. Stage distribution in the cohort was as follows: I 17% (n = 173), II 37% (n = 388), III 35% (n = 368), and IV 8% (n = 88). For all patients, 2-year OS was 67%. In multivariable Cox regression, worse OS was associated with stage: II (HR 1.91, p = 0.007), III (HR 3.99, p < 0.001), and IV (HR 5.06, p < 0.001) compared to stage I. Improved OS was associated with hemoglobin > 10 g/dL (HR 0.51, p < 0.001) compared to Hb ≤ 10 g/dL.

Conclusions: Among women in Botswana with cervical cancer, most patients presented with stage II or III disease warranting radiation therapy or chemoradiation. While two-thirds of cervical cancer patients were women living with HIV, HIV did not impact OS.

Keywords: Cervical cancer; Chemoradiation; HIV; Outcomes; Stage.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Survival outcomes by stage- Stage was inversely proportional to patients’ 2-year OS rates among the entire cohort: stage I 88.0% (95% CI 83.0–93.4%), stage II 77.5% (95% CI 73.3–81.9%), stage III 54.3% (95% CI 49.2–59.9%), and stage IV 40% (95% CI 30.8–52.2%) (log rank, p < 0.001).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Brachytherapy Society. Brachytherapy guidelines and consensus statements.
    1. Asamoah F.A., Yarney J., Scott A., et al. Comparison of Definitive Cervical Cancer Management With Chemotherapy and Radiation Between Two Centers With Variable Resources and Opportunities for Improved Treatment. JCO Glob Oncol. 2020;6:1510–2158. - PMC - PubMed
    1. Awolude O.A., Oyerinde S.O. Invasive cervical cancer in ibadan: Socio-sexual characteristics, clinical stage at presentation, histopathology distributions and hiv status. Afr J Infect Dis. 2019;13:32–38. - PMC - PubMed
    1. Barchi F., Winter S.C., Ketshogile F.M., Ramogola-Masire D. Adherence to screening appointments in a cervical cancer clinic serving HIV-positive women in Botswana. BMC Public Health. 2019;19:1–13. - PMC - PubMed
    1. Bhatla N., Berek J.S., Fredes M.C., et al. Revised FIGO staging for carcinoma of the cervix uteri. Int. J. Gynaecol. Obstet. 2019;145:129–135. - PubMed